S. I. Kim

7304 Background: The aim of this study was to compare the treatment outcomes of crossover treatments with paclitaxel- or gemcitabine-based combination chemotherapy for non-small-cell lung cancer (NSCLC). Methods: A retrospective analysis was performed on newly diagnosed patients with stage IIIB or IV NSCLC who had received either paclitaxel (P)- followed by gemcitabine (G)-based chemotherapy (P→G; group A) or gemcitabine- followed by paclitaxel-based chemotherapy (G→P; group B). A total of 157 patients were evaluated. All the patients received combination chemotherapy with platinum compounds in the first-line treatment but either vinorelbine or platinum was added to the second-line chemotherapy. Results: There patient characteristics of group A (n=115) and group B (n=42) were similar. The response rates of the first-line treatment were 46% for group A, 33% for group B (p=0.185), and response rates of the second-line treatment were 26% and 38%, respectively (p=0.143). The maximum cumulative response rates of the first- and second-line treatments were 61.7% for group A, 57.1% for group B (p=0.602). The time to progression of the first-line chemotherapy was 4.1 months for group A, 4.4 months for group B (p=0.9736), and for the second-line chemotherapy, it was 3.4 months and 3.9 months (p=0.7100). The median overall survival times were 18.9 months and 15.0 months, respectively (p=0.1420). Conclusions: There was no difference in terms of the response rates, the maximum cumulative response rates, the time to progression, and the overall median survival time as to whether the NSCLC patients received paclitaxel- followed by gemcitabine-based chemotherapy or gemcitabine- followed by paclitaxel-based chemotherapy. No significant financial relationships to disclose.

7304 Background: The aim of this study was to compare the treatment outcomes of crossover treatments with paclitaxel- or gemcitabine-based combination chemotherapy for non-small-cell lung cancer (NSCLC). Methods: A retrospective analysis was performed on newly diagnosed patients with stage IIIB or IV NSCLC who had received either paclitaxel (P)- followed by gemcitabine (G)-based chemotherapy (P→G; group A) or gemcitabine- followed by paclitaxel-based chemotherapy (G→P; group B). A total of 157 patients were evaluated. All the patients received combination chemotherapy with platinum compounds in the first-line treatment but either vinorelbine or platinum was added to the second-line chemotherapy. Results: There patient characteristics of group A (n=115) and group B (n=42) were similar. The response rates of the first-line treatment were 46% for group A, 33% for group B (p=0.185), and response rates of the second-line treatment were 26% and 38%, respectively (p=0.143). The maximum cumulative response rates of the first- and second-line treatments were 61.7% for group A, 57.1% for group B (p=0.602). The time to progression of the first-line chemotherapy was 4.1 months for group A, 4.4 months for group B (p=0.9736), and for the second-line chemotherapy, it was 3.4 months and 3.9 months (p=0.7100). The median overall survival times were 18.9 months and 15.0 months, respectively (p=0.1420). Conclusions: There was no difference in terms of the response rates, the maximum cumulative response rates, the time to progression, and the overall median survival time as to whether the NSCLC patients received paclitaxel- followed by gemcitabine-based chemotherapy or gemcitabine- followed by paclitaxel-based chemotherapy. No significant financial relationships to disclose.